Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Isaacs

Showing results (431-440 of 499) with videos related to

Pageof 50
Sort By:
The Prostate|January 16, 2016
Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trialDanyelle A Winchester, Bora Gurel, Cathee Till, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 26, 2020
Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention TrialLauren M Hurwitz, Ibrahim Kulac, Berrak Gumuskaya, et al.
Cancer Research|November 3, 2006
Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer riskXianshu Wang, Fengwei Wang, Ken Taniguchi, et al.
The Prostate|June 15, 2011
Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analysesYizhen Lu, Jielin Sun, Andrew K Kader, et al.
The New England Journal of Medicine|January 18, 2008
Cumulative association of five genetic variants with prostate cancerS Lilly Zheng, Jielin Sun, Fredrik Wiklund, et al.
The Prostate|June 6, 2015
Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention TrialDanyelle A Winchester, Cathee Till, Phyllis J Goodman, et al.
Cancer Letters|June 24, 2008
Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancerMarc D Tischkowitz, Ahmet Yilmaz, Long Q Chen, et al.
The New England Journal of Medicine|September 4, 2014
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancerEmmanuel S Antonarakis, Changxue Lu, Hao Wang, et al.
JCI Insight|March 16, 2021
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancerW Nathaniel Brennen, Yezi Zhu, Ilsa M Coleman, et al.
Oncogene|December 6, 2011
Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancerW Liu, J Lindberg, G Sui, et al.
Pageof 50

Showing results (431-440 of 499) with videos related to

Sort By:
Pageof 50
The Prostate|January 16, 2016
Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trialDanyelle A Winchester, Bora Gurel, Cathee Till, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 26, 2020
Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention TrialLauren M Hurwitz, Ibrahim Kulac, Berrak Gumuskaya, et al.
Cancer Research|November 3, 2006
Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer riskXianshu Wang, Fengwei Wang, Ken Taniguchi, et al.
The Prostate|June 15, 2011
Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analysesYizhen Lu, Jielin Sun, Andrew K Kader, et al.
The New England Journal of Medicine|January 18, 2008
Cumulative association of five genetic variants with prostate cancerS Lilly Zheng, Jielin Sun, Fredrik Wiklund, et al.
The Prostate|June 6, 2015
Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention TrialDanyelle A Winchester, Cathee Till, Phyllis J Goodman, et al.
Cancer Letters|June 24, 2008
Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancerMarc D Tischkowitz, Ahmet Yilmaz, Long Q Chen, et al.
The New England Journal of Medicine|September 4, 2014
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancerEmmanuel S Antonarakis, Changxue Lu, Hao Wang, et al.
JCI Insight|March 16, 2021
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancerW Nathaniel Brennen, Yezi Zhu, Ilsa M Coleman, et al.
Oncogene|December 6, 2011
Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancerW Liu, J Lindberg, G Sui, et al.
Pageof 50